HAMP and congenital dyserythropoietic anemia type 2: Clinically, CDA II patients present with ineffective erythropoiesis that leads to downregulation of the hepcidin hormone; this increases iron absorption and can drive systemic iron overload, a main complication in CDA II patients [15].